헤모글로빈 이상증 치료 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, hemoglobinopathies treatment market size in 2026 is estimated at USD 11.45 billion, growing from 2025 value of USD 10.61 billion with 2031 projections showing USD 16.72 billion, growing at 7.88% CAGR over 2026-2031.

This report is Segmented by Treatment (Stem Cell Transplantation, Blood Transfusion, Iron Chelation Therapy, Pharmacological Agents, and More), Application (Thalassemia, and More), Route of Administration (Oral, Parenteral, and Transfusion), End User (Hospitals, Specialty Clinics, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Hemoglobinopathies Treatment Market Trends and Insights

First-in-class gene-therapy approvals accelerate adoption

FDA clearance of CASGEVY and LYFGENIA between late-2023 and early-2024 has reshaped clinician expectations around curative options. Post-approval real-world data show 94% of evaluable patients eliminating severe vaso-occlusive events within the first 18 months of follow-up. European Medicines Agency authorization widens access across 27 member states and signals a harmonized regulatory pathway for subsequent CRISPR platforms. Early clinical success is driving referral patterns toward definitive therapy, particularly among adolescents who aim to avoid lifelong transfusions and chelation. Treatment centers report rising wait-lists, prompting investments in vector-manufacturing capacity and apheresis infrastructure. The acceleration of gene-therapy uptake is expected to lift the hemoglobinopathies treatment market through premium pricing and extended survival benefits.

Expanding newborn & antenatal screening programs

Mandated screening across high-burden states in India, coupled with roll-outs in Nigeria and Brazil, is enabling earlier diagnosis and linkage to care. India's multicentric cohort initiative spans seven tertiary hospitals and integrates digital registries for longitudinal follow-up. WHO modeling indicates universal screening could avert 70% of sickle-cell-related mortality, galvanizing donor-funded laboratory upgrades across Sub-Saharan Africa. Rapid diagnostics such as the Gazelle multispectral reader achieve 96.8% accuracy within 3 days of birth. In advanced markets, dual-review antenatal protocols standardize result interpretation and improve counseling uptake. Earlier identification expands the candidate pool for curative therapies and supports sustainable volume growth in the hemoglobinopathies treatment market.

High cost of curative therapies

List prices above USD 2 million constrain immediate uptake, prompting insurers to demand long-horizon cost-effectiveness analyses. In several EU states, pay-for-performance models defer 70% of payment until patients remain transfusion-free for two years. Low-income settings negotiate deep discounts but still face supply-chain mark-ups tied to cold-storage logistics. Manufacturer assistance programs mitigate some patient liability yet are limited by budget caps. Until biosimilar or allogeneic off-the-shelf options emerge, sticker shock will temper the upward curve of the hemoglobinopathies treatment market.

Other drivers and restraints analyzed in the detailed report include:

1. Rare-disease reimbursement roll-outs in middle-income nations
2. AI-enabled point-of-care diagnostics integration
3. Donor-match scarcity for stem-cell transplantation

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The hemoglobinopathies treatment market size for gene therapy is projected to rise at a 19.06% CAGR, whereas blood transfusion maintains a 37.89% share in 2025. Regulatory wins for CRISPR-based products validate one-time curative economics and ignite global pipeline investment. Vertex-CRISPR Therapeutics intend to scale vector capacity by three times to meet US and EU demand waves. Stem-cell transplantation remains curative but is limited by donor availability and graft-versus-host risks, preserving a role for gene-edited autologous options.

Pharmacological disease-modifiers such as voxelotor and crizanlizumab preserve value in regions where reimbursement for gene therapy lags. Iron chelation therapy, indispensable for transfusion-dependent thalassemia, grows steadily alongside decentralized transfusion networks. Emerging base-editing candidates from CorrectSequence illustrate the geographic broadening of innovation as China and Singapore accelerate trial approvals. Overall, treatment-mix evolution favors technologies offering durable benefit, positioning curative platforms as the primary driver of qualitative change in the hemoglobinopathies treatment market.

Sickle cell disease controls 48.03% of hemoglobinopathies treatment market share in 2025 and benefits from decades of standardized care pathways in North America and Europe. Nonetheless, thalassemia's 10.73% CAGR leads the application set, propelled by Mediterranean and South-East Asian screening mandates that convert latent carriers into managed patients. Luspatercept trials for alpha-thalassemia HbH disease highlight ongoing therapeutic diversification beyond transfusion reliance. The Thalassemia International Federation's digital patient registry improves adherence monitoring and underpins payer negotiations for high-cost therapies. Rare variants, including hemoglobin E disorders, gain visibility through next-generation sequencing programs but remain commercialization niches. With distinct epidemiological footprints, application growth vectors hinge on regional policy implementation and culturally tailored outreach, reinforcing divergent yet complementary flows within the hemoglobinopathies treatment market.

Complete Report Scope:

• By Treatment
  • Stem Cell Transplantation
  • Blood Transfusion
  • Iron Chelation Therapy
  • Pharmacological Agents
  • Gene Therapy
  • Other Supportive Treatments
• By Application
  • Thalassemia
  • Sickle Cell Disease
  • Other Hemoglobinopathies
• By Route of Administration
  • Oral
  • Parenteral
  • Transfusion
• By End User
  • Hospitals
  • Specialty Clinics
  • Academic & Research Institutes
  • Others
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America leads the hemoglobinopathies treatment market size with 34.92% share in 2025, benefiting from robust insurance coverage and early adoption of FDA-approved curative options. Gene-therapy infusion centers have doubled since 2023, and outcome-based reimbursement pilots underpin continued premium pricing. Europe follows, leveraging EMA regulatory cohesion and public health systems that swiftly incorporated CASGEVY into rare-disease formularies. Pan-EU joint procurement discussions aim to secure bulk-buy discounts, potentially widening hospital adoption while preserving manufacturer margins.

Asia-Pacific will post the fastest 9.43% CAGR through 2031, driven by high carrier prevalence in India, Thailand, and southern China. India's National Health Mission funds state-level newborn screening which, coupled with public-private partnerships, funnels newly diagnosed infants into treatment pipelines. China's National Medical Products Administration granted priority review to domestic base-editing therapies, signaling policy support for indigenous innovation and import alternatives. Southeast Asian nations expand thalassemia day-care units, concentrating transfusion services and accelerating chelation sales. Collectively these initiatives elevate both volume and complexity of care, amplifying regional influence on global supply-chain planning for the hemoglobinopathies treatment market.

Middle East & Africa face infrastructural gaps: Nigeria's national sickle-cell policy sets ambitious targets, yet cold-chain deficits limit biologic penetration. Pilot decentralized transfusion hubs in Ghana cut rural travel times by 40%, indicating scalable blueprints for broader implementation. South America maintains moderate growth; Brazil's rare-disease ordinance and inclusion of hydroxyurea in the national formulary stimulate steady demand. Across regions, heterogeneity in healthcare financing, genetic prevalence, and technology adoption will continue to shape disparate yet interlinked trajectories for the hemoglobinopathies treatment market.

1. Sanofi
2. Novartis
3. Pfizer
4. bluebird bio
5. Vertex Pharmaceuticals
6. CRISPR Therapeutic
7. Sangamo Therapeutics
8. Gamida Cell
9. Emmaus Life Sciences
10. CSL Behring
11. Agios Pharmaceuticals
12. Editas Medicine
13. Intellia Therapeutics
14. Rocket Pharmaceuticals
15. Acceleron Pharma
16. Silence Therapeutics
17. Vifor Pharma
18. Bioverativ (Genzyme unit)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Prevalence Of Hemoglobinopathies
  • 4.2.2 Expanding Newborn & Antenatal Screening Programs
  • 4.2.3 First-In-Class Gene-Therapy Approvals Accelerate Adoption
  • 4.2.4 Government Rare-Disease Reimbursement Roll-Outs In Middle-Income Nations
  • 4.2.5 Decentralized Blood-Transfusion Networks In Sub-Saharan Africa
  • 4.2.6 AI-Enabled Point-Of-Care Diagnostics Integration
• 4.3 Market Restraints
  • 4.3.1 High Cost Of Curative Therapies
  • 4.3.2 Donor-Match Scarcity For Stem-Cell Transplantation
  • 4.3.3 Cold-Chain Gaps For Biologics In Tropical Markets
  • 4.3.4 Regulatory Ambiguity For CRISPR-Edited Products
• 4.4 Porter's Five Forces
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Treatment
  • 5.1.1 Stem Cell Transplantation
  • 5.1.2 Blood Transfusion
  • 5.1.3 Iron Chelation Therapy
  • 5.1.4 Pharmacological Agents
  • 5.1.5 Gene Therapy
  • 5.1.6 Other Supportive Treatments
• 5.2 By Application
  • 5.2.1 Thalassemia
  • 5.2.2 Sickle Cell Disease
  • 5.2.3 Other Hemoglobinopathies
• 5.3 By Route of Administration
  • 5.3.1 Oral
  • 5.3.2 Parenteral
  • 5.3.3 Transfusion
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Specialty Clinics
  • 5.4.3 Academic & Research Institutes
  • 5.4.4 Others
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Sanofi SA
  • 6.3.2 Novartis AG
  • 6.3.3 Pfizer Inc.
  • 6.3.4 bluebird bio
  • 6.3.5 Vertex Pharmaceuticals
  • 6.3.6 CRISPR Therapeutics
  • 6.3.7 Sangamo Therapeutics
  • 6.3.8 Gamida Cell
  • 6.3.9 Emmaus Life Sciences
  • 6.3.10 CSL Behring
  • 6.3.11 Agios Pharmaceuticals
  • 6.3.12 Editas Medicine
  • 6.3.13 Intellia Therapeutics
  • 6.3.14 Rocket Pharmaceuticals
  • 6.3.15 Acceleron Pharma
  • 6.3.16 Silence Therapeutics
  • 6.3.17 Vifor Pharma
  • 6.3.18 Bioverativ (Genzyme unit)

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment